##semicolon##
chronic interstitial lung injury; diabetes mellitus; alloxan; bitter almond oil; Herbion®; oxidative stress; malondialdehyde; surfactant protein A; surfactant protein D; KL-40; neutrophil elastase; phytotherapy.##submission.citations##
1. Avdeev SN. Interstitsial'nye zabolevaniya legkikh: prakticheskoe rukovodstvo [Interstitial lung diseases: practical guide]. Moscow: GEOTAR-Media; 2015. (In Russian).
2. Andreeva LI, Kozhemyakin LA, Kishkun AA. Modifikatsiya metoda opredeleniya perekisey lipidov v teste s tiobarbiturovoy kislotoy [Modification of the method for determination of lipid peroxides using the thiobarbituric acid assay]. Laboratornoe Delo. 1988;(1):41-43. (In Russian).
3. Batyn SZ, Chernyak AV, Neklyudova GV, et al. Khronicheskie neinfektsionnye zabolevaniya: sovremennye podkhody k profilaktike [Chronic non-communicable diseases: modern approaches to prevention]. 2013. (In Russian).
4. Birulina YG, Voronkova OV, Ivanov VV, Buyko EE, Shcherbakova MM, Chernyshov NA, et al. Markery sistemnogo vospaleniya u krys v modeli diet-indutsirovannogo metabolicheskogo sindroma [Markers of systemic inflammation in rats with diet-induced metabolic syndrome]. Vestnik RGMU. 2022;(4):43-49. doi:10.24075/vrgmu.2022.043. (In Russian).
5. O'zDSt 2762:2018. Good Laboratory Practice (GLP). Tashkent; 2018.
6. Dvoretskiy LI. Idiopaticheskiy legochnyy fibroz: diagnostika, lechenie, prognoz [Idiopathic pulmonary fibrosis: diagnosis, treatment and prognosis]. 2014. (In Russian).
7. Kayumova YD, Tadzhikhodzhaeva YKh. Eksperimental'naya model' khronicheskoy obstruktivnoy bolezni legkikh s tabakokureniem v izuchenii membranodestruktivnykh protsessov [Experimental model of chronic obstructive pulmonary disease induced by tobacco smoke for studying membrane-destructive processes]. Vestnik Assotsiatsii Pul'monologov Tsentral'noy Azii. 2020;18(1-4):22-26. (In Russian).
8. Leonova EI, Shmelev EI, Shergina N. Izmeneniya sosudistoy zhestkosti pri idiopaticheskom fibroze legkikh [Changes in vascular stiffness in idiopathic pulmonary fibrosis]. 2019. (In Russian).
9. Orlova GP, Surkova EA, Lapin SV. Diagnosticheskie biomarkery pri interstitsial'nykh zabolevaniyakh legkikh [Diagnostic biomarkers in interstitial lung diseases]. 2016. (In Russian).
10. Stefanov AV. Doklinicheskie issledovaniya lekarstvennykh sredstv [Preclinical studies of medicinal products]. Kyiv; 2002. p.91. (In Russian).
11. Stupnitskaya AYa. Khronicheskoe sistemnoe vospalenie pri KhOBL i metabolicheskom sindrome [Chronic systemic inflammation in COPD and metabolic syndrome]. 2014. (In Russian).
12. Fedorova EP, Filonova MV, Dubskaya TYu, Vetoshkina TV, Sandrikina LA, Fomina TI, Neupokoeva OV, Minakova MYu, Churin AA. Izuchenie narusheniy sistem zhizneobespecheniya organizma v usloviyakh eksperimental'nogo porazheniya legkikh [Study of disturbances in life-support systems under experimental lung injury]. Vestnik SurGU. Meditsina. 2024;(4):75-81. (In Russian).
13. Chuchalin AG. Profilaktika i kontrol' khronicheskikh neinfektsionnykh zabolevaniy [Prevention and control of chronic non-communicable diseases]. Pul'monologiya. 2009;(1):5-10. (In Russian).
14. Blackwell TS, Tager AM, Borok Z, et al. Future directions in idiopathic pulmonary fibrosis research. Am J Respir Crit Care Med. 2014;189(2):214-222.
15. Vidal Drug Reference. Ecdisten. Available from: https://www.vidal.ru/drugs/ecdisten__33965. Accessed July 9, 2026.
16. Coultas D.B., Zumwalt R.E., Black W.C., Sobonya R.E. The epidemiology of interstitial lung diseases. // Am J Respir Crit Care Med. – 1994; 150(4): 967–972.
17. Fernández Pérez E.R., Daniels C.E., Schroeder D.R. Incidence and prevalence of idiopathic pulmonary fibrosis. // Chest. – 2010; 137(1): 129–137.
18. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Strategy for the Diagnosis, Management, and Prevention of COPD. – 2013.
19. Gribbin J., Hubbard R.B., Le Jeune I. et al. Incidence and mortality of idiopathic pulmonary fibrosis. // Thorax. – 2006; 61(11): 980–985.
20. Hocher B., Schwarz A., Fagan K.A. et al. Endothelin-1 and pulmonary fibrosis. // Kidney Int. – 2000; 57(6): 2465–2475.
21. Kulasekaran P., Scavone C.A., Rogers D.S. et al. TGF-β and endothelin-1 signaling in pulmonary fibrosis. // Am J Respir Cell Mol Biol. – 2009; 40(6): 791–799.
22. Maher T.M. Idiopathic pulmonary fibrosis: pathobiology and novel approaches to treatment. // Clin Chest Med. – 2012; 33(1): 69–83.
23. Patel A.R.C., Hurst S.R. Inflammation and metabolic disturbances in COPD. // Respir Med. – 2011; 105(9): 1323–1330.
24. Peljto A.L., Zhang Y., Fingerlin T.E. et al. The MUC5B promoter polymorphism is associated with pulmonary fibrosis. // N Engl J Med. – 2013; 368(3): 219–228.
25. Raghu G., Weycker D., Edelsberg J. et al. Incidence and prevalence of idiopathic pulmonary fibrosis. // Am J Respir Crit Care Med. – 2006; 174(7): 810–816.
26. Ryu J.H., Moua T., Daniels C.E. et al. Diagnosis of interstitial lung diseases. // Mayo Clin Proc. – 2014; 89(6): 777–784.
27. Vij R., Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. // Transl Res. – 2012; 159(4): 218–227.
28. Wahidi M.M., Speer M.C., Steele M.P. et al. Familial pulmonary fibrosis. // Chest. – 2002; 121(6): 2068–2074.
29. Wang Y., Kuan P.J., Xing C. et al. Genetic studies in familial pulmonary fibrosis. // Am J Respir Crit Care Med. – 2009; 179(5): 367–373.
30. Xia H., Bodempudi V., Benyumov A. et al. Fibroblast recruitment and proliferation in pulmonary fibrosis. // J Biol Chem. – 2014; 289(7): 4790–4802.
31. Xu J., Gonzalez E.T., Iyer S.S. et al. TGF-beta1 mediates fibroblast recruitment in pulmonary fibrosis. // J Clin Invest. – 2009; 119(1): 78–91.
32. Zhang Y., Kaminski N. Biomarkers in idiopathic pulmonary fibrosis. // Respirology. – 2012; 17(3): 451–462.